Adagene Ausschüttungen und Rückkäufe

Zukünftiges Wachstum Kriterienprüfungen 0/6

Adagene hat in der Vergangenheit keine Dividende gezahlt.

Wichtige Informationen

n/a

Dividendenausschüttung

-0.04%

Rückkaufsrendite

Gesamte Aktionärsrendite	-0.04%
Zukünftige Dividendenrendite	0%
Wachstum der Dividende	n/a
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Ausschüttungsquote	n/a

Jüngste Updates zu Dividenden und Rückkäufen

Recent updates

Adagene Inc. (NASDAQ:ADAG) Surges 26% Yet Its Low P/S Is No Reason For Excitement

Oct 10

The Consensus EPS Estimates For Adagene Inc. (NASDAQ:ADAG) Just Fell Dramatically

Oct 05

Adagene ADR GAAP EPS of -$0.87 misses by $0.45, revenue of $3.93M misses by $9.82M

Aug 30

Micro-cap Adagene surges after hours on $10M share buyback

Jun 29

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von ADAG in der Vergangenheit stabil war.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von ADAG gestiegen sind.

Dividendenrendite im Vergleich zum Markt

Adagene Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von ADAG im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (ADAG)	n/a
Untere 25 % des Marktes (US)	1.4%
Markt Top 25 % (US)	4.2%
Branchendurchschnitt (Biotechs)	2.3%
Analystenprognose (ADAG) (bis zu 3 Jahre)	0%

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von ADAG im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von ADAG im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von ADAG, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da ADAG keine Ausschüttungen gemeldet hat.

Adagene Ausschüttungen und Rückkäufe

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Updates zu Dividenden und Rückkäufen

Adagene Inc. (NasdaqGM:ADAG) announces an Equity Buyback for $10 million worth of its shares.

Recent updates

New minor risk - Market cap size

New major risk - Revenue and earnings growth

Full year 2023 earnings released: US$1.83 loss per share (vs US$1.85 loss in FY 2022)

Adagene Inc. Announces Board Changes

New minor risk - Financial data availability

Adagene Inc. Appoints Heinz-Josef Lenz to Scientific and Strategic Advisory Board

Adagene Inc. Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody

New major risk - Share price stability

Adagene Inc. Announces Data from its Presentation at the American Society of Clinical Oncology 2024 Gastrointestinal (GI) Cancers Symposium

Adagene Inc. Presents Data Demonstrating the Best-In-Class Therapeutic Index for Masked Anti-CTLA-4 Safebody®? Adg126

Adagene Inc. (NASDAQ:ADAG) Surges 26% Yet Its Low P/S Is No Reason For Excitement

New major risk - Revenue and earnings growth

Price target decreased by 32% to US$9.16

Full year 2022 earnings released: US$1.85 loss per share (vs US$1.83 loss in FY 2021)

Price target decreased by 9.4% to US$12.53

Adagene Announces Interim Data Demonstrating Safety and Confirmed Clinical Responses of Anti-Ctla-4 Safebody® Adg126 Up to 10 Mg/Kg with Repeat Cycles in Combination with Anti-Pd-1 Therapy from Dose Escalation Portion of Phase 1B/2 Trial

Price target increased to US$13.82

Price target decreased to US$10.78

Adagene Inc. Appoints Cuong Do to Board of Directors and Audit Committee

Price target decreased to US$12.71

High number of new and inexperienced directors

Adagene Announces Clinical Data at SITC 2022 on Anti-CTLA-4 NEObody™, ADG116, Showing Differentiated Safety and Anti-tumor Activity in Heavily Pre-treated Patients with Difficult-to-Treat Tumors

The Consensus EPS Estimates For Adagene Inc. (NASDAQ:ADAG) Just Fell Dramatically

Consensus forecasts updated

Adagene Inc. Presents Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-Tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody® ADG126 in Patients with Advanced Tumors

Price target increased to US$27.92

First half 2022 earnings released: US$1.09 loss per share (vs US$1.02 loss in 1H 2021)

Adagene ADR GAAP EPS of -$0.87 misses by $0.45, revenue of $3.93M misses by $9.82M

Adagene Inc. (NasdaqGM:ADAG) announces an Equity Buyback for $10 million worth of its shares.

Micro-cap Adagene surges after hours on $10M share buyback

Adagene Announces Publication at ASCO of Interim Monotherapy Dose Escalation Data Showing Compelling Safety Profile of Anti-CTLA-4 SAFEbody ADG126, with Repeat Dosing Across Dose Levels

High number of new and inexperienced directors

Adagene Inc. Presents Data Demonstrating First and Best-In-Class Potential for Differentiated Preclinical Antibody Candidates At American Association for Cancer Research (Aacr) Annual Meeting 2022

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$25.69

Adagene Inc. Announces Board and Management Changes

Adagene Announces First Patient Dosed with Novel, Proprietary Combination of Anti-CD137 Agonist, ADG106, and Anti-CTLA-4 Monoclonal Antibody, ADG116

Adagene Inc. Announces First Patients with Advanced Non-Small Cell Lung Cancer Dosed in Phase 1B/2 Clinical Trial of ADG106 in Combination with Nivolumab in Singapore

Adagene Announces FDA Clearance of IND for Phase 1b/2 Trial of Anti-CTLA-4 Monoclonal Antibody ADG116 in Combination Therapy with Anti-PD-1 Antibody Pembrolizumab

Director Yu Miao has left the company

Adagene Inc. Announces Clinical Data from its ADG106 NEObodyTM Program

Adagene Inc. Announces First Patients Dosed in Global Phase 1 Clinical Trial of ADG126 for the Treatment of Various Advanced Solid Tumors

Adagene Inc. has completed an IPO in the amount of $139.726 million.

Stabilität und Wachstum des Zahlungsverkehrs

Dividendenrendite im Vergleich zum Markt

Gewinnausschüttung an die Aktionäre

Barausschüttung an die Aktionäre

Entdecken Sie dividendenstarke Unternehmen